Paid Clinical Trials Ogden
Discover 1,044 paid clinical trials in Ogden, Utah. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
BEM/RZR vs. SOF/VELC-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
Sponsor:
Atea Pharmaceuticals, Inc.
Location:
Code:
NCT06868264
Conditions
HEPATITIS C VIRUS CHRONIC INFECTION
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Bemnifosbuvir-Ruzasvir (BEM/RZR)
Sofosbuvir-Velpatasvir (SOF/VEL)
Odronextamab & RituximabA Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
Sponsor:
Regeneron Pharmaceuticals
Location:
Code:
NCT06097364
Conditions
Follicular Lymphoma (FL)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Odronextamab
Rituximab
Cyclophosphamide
Doxorubicin
Vincristine
Targeted TherapiesStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Sponsor:
AbbVie
Location:
Code:
NCT06548542
Conditions
Crohn's Disease
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Risankizumab
Lutikizumab
ABBV-382
IanalumabStudy of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
Sponsor:
Novartis Pharmaceuticals
Location:
Code:
NCT05653349
Conditions
Primary Immune Thrombocytopenia (ITP)
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Ianalumab
Placebo
Corticosteroids
Amlitelimab with CorticosteroidsA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
Sponsor:
Sanofi
Location:
Code:
NCT06241118
Conditions
Dermatitis Atopic
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Amlitelimab
Placebo
Topical corticosteroids
Topical tacrolimus or pimecrolimus
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Pneumococcal Conjugate VaccineStudy of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Sponsor:
Sanofi Pasteur, a Sanofi Company
Location:
Code:
NCT06736041
Conditions
Pneumococcal Immunization
Eligibility Criteria
Sex: All
Age: 42 - 70+
Healthy Volunteers: Accepted
Interventions
PCV21 vaccine
Prevnar 20 vaccine
M-M-R II vaccine
RotaTeq
Vaxelis vaccine
CryoablationCryoablation of Small Breast Tumors in Early Stage Breast Cancer
Sponsor:
Sanarus Technologies, Inc.
Location:
Code:
NCT01992250
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 50+
Healthy Volunteers: Not accepted
Interventions
Visica 2 Treatment System
VVD-159642A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
Sponsor:
Vividion Therapeutics, Inc.
Location:
Code:
NCT06804824
Conditions
Advanced Solid Tumors
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
VVD-159642
Sotorasib
Trametinib
TEACHTelehealth-Enabled, Real-time Audit and Feedback for Clinician AdHerence (TEACH)
Sponsor:
Intermountain Health Care, Inc.
Location:
Code:
NCT05141396
Conditions
Respiration, Artificial
Eligibility Criteria
Sex: All
Age: 16+
Healthy Volunteers: Not accepted
Interventions
Telehealth- enabled support for SAT/SBT adherence
Usual audit and feedback for SAT/SBT adherence
Epcoritamab & LenalidomideA Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sponsor:
Genmab
Location:
Code:
NCT06508658
Conditions
Diffuse Large B-Cell Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Epcoritamab
Rituximab
Lenalidomide
Oxaliplatin
Gemcitabine